BSE: AARTIDRUGS - Aarti Drugs Limited

半年間の収益性: -27.41%
配当利回り: +0.25%

プロモーションスケジュール Aarti Drugs Limited


会社について Aarti Drugs Limited

Aarti Drugs Limited, through its subsidiaries, manufactures and markets active pharmaceutical ingredients (APIs), pharmaceutical intermediates, specialty chemicals, and formulations in India and internationally.

さらに詳しく
The company offers aceclofenac, celecoxib, diclofenac sodium, diclodenac potassium, diclofenac diethylamine, diclofenac resinate, diclofenac epolamine, nimesulide, ciprofloxacin HCL, enrofloxacin base, gatifloxacin sesquihydrate, levofloxacin base, moxifloxacin, norfloxacin, ofloxacin, metronidazole benzoate, ornidazole, secnidazole, tinidazole, clopidogrel bisulphate, ticlopidine HCL, metformin HCL, pioglitazone HCL, teneligliptin, vildagliptin, fluconazole, ketoconazole, tolnaftate, zolpidem tartrate, niacin, raloxifene HCL, and acamprosate. It also provides benzene sulphonyl chloride, benzene sulphonic acid, benzene sulphonic acid methyl ester, sodium benzene sulfinate, para toluene sulphonyl chloride, methyl para toluenesulfonate, sodium para toluenesulfinate, para chlorobenzenesulfonyl chloride, formamide, calcium fluoride, potasium formate, benzenesulfonamide, ethyl p- toluenesulfonate, N,N',N'-tris-(4-toluene sulfonyl)-diethylenetriamine, ortho para toluene sulfonamides, ortho para toluene sulfonamides acid methyl ester, para chlorobenznesulfonamide, para toluenesulfonyl hydrazide, para toluenesulfonamide, and sodium benzenesulfonate. In addition, it offers pharma intermediate products, which includes Celecoxib, Ciprofloxacin, Clopidogrel, Diclofenac, Ketoconazole, Nimesulide, Raloxifene, Tinidazole, and Zolpidem. Further, the company develops drugs for the antioxidant, antifungal, cardiovascular, and antidiabetic therapeutic areas. The company was incorporated in 1984 and is headquartered in Mumbai, India.

ISIN INE767A01016
Industry Pharmaceuticals
Sector Health Care
Валюта inr
Валюта отчета inr
Див.доход ао 0.2464
Дивиденд ао 1
Сайт https://www.aartidrugs.co.in
Цена ао 333.65
1日あたりの価格変動: -4.11% (365.75)
週ごとの価格変動: -1.89% (357.45)
月ごとの料金変更: +5.11% (333.65)
3ヶ月間の価格変動: -14.34% (409.4)
半年間の価格変動: -27.41% (483.15)
年間の価格変動: -29.92% (500.4)
3年間の価格推移: -26.94% (480)
5年間の価格推移: -31.95% (515.35)
年初からの価格変動: -23.87% (460.65)

過小評価

名前 意味 学年
P/S 1.67 8
P/BV 3.27 5
P/E 24.43 6
EV/EBITDA 12.94 7
合計: 6.75

効率

名前 意味 学年
ROA, % 7.06 2
ROE, % 13.86 4
合計: 3.67

配当金

名前 意味 学年
Div yield, % 0.2464 0.63
DSI 0.9286 9.29
合計: 1.63

義務

名前 意味 学年
Debt/EBITDA 1.83 7
合計: 7.4

成長の衝動

名前 意味 学年
収益性 Revenue, % 38.91 5
収益性 Ebitda, % 44.13 6
収益性 EPS, % -43.02 0
合計: 3

スーパーバイザー 役職 支払い 生年
Mr. Prakash Moreshwar Patil Chairman, MD, CEO & Head of BR 27.65M 1947 (78 年)
Mr. Harshit Manila Savla Joint MD & Executive Director 25.55M 1962 (63 年)
Mr. Harit Pragji Shah Whole-Time Director 25.55M 1963 (62 年)
Mr. Uday Moreshwar Patil Whole-Time Director 3.19M 1963 (62 年)
Mr. Rashesh Chandrakant Gogri MD & Executive Director 25.55M 1974 (51 年)
Mr. Adhish Prakash Patil CFO & COO N/A 1983 (42 年)
Mr. Dhanaji L. Kakade Vice President of Technical N/A
Mr. Vishwa Harshit Savla Managing Director of the Pinnacle Life Science Private Limited N/A
Mr. Rushikesh Vivek Deole Company Secretary & Compliance Officer N/A

住所: India, Mumbai, Mahendra Industrial Estate - Googleマップで開く, Yandexマップを開く
Webサイト: https://www.aartidrugs.co.in